Roger C.Rich Ph.D.

Counsel

Silicon Valley + 1.650.739.3947

Connect:

Share

Dr. Roger Rich represents companies in areas of patent law related to biotechnology and pharmaceuticals. He advises clients in the strategic development, management, and prosecution of patent portfolios involving technologies such as small molecule pharmaceuticals, genetic analyses, biologics, nutraceuticals, and transgenic animals, among others. Representative clients have included AbbVie, Acadia Pharmaceuticals, Amgen, AstraZeneca, Becton Dickinson, and Genentech, as well as other start-up companies, established companies, academic institutions, and investment firms.

In addition to patent procurement and portfolio management, Roger advises clients regarding patentability, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios for possible investment, licensing, or acquisition.

Experience

  • ToolGen faces off in two patent interferences involving CRISPR/Cas9 applicationJones Day is representing ToolGen, Inc. in two patent interferences involving CRISPR/Cas9 technology.
  • ToolGen obtains ex parte PTAB appeal victory reversing examiner's rejections in CRISPR patent applicationOn June 22, 2020, Jones Day obtained a decision on behalf of ToolGen, Inc. at the United States Patent Trial and Appeal Board ("PTAB") reversing all of the examiner's obviousness rejections of the claims in ToolGen's U.S. Patent Application No. 14/685,510 (Appeal No. 2019-001990).
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Athyrium Capital Management refinances Biom'Up's existing debt, finances production and marketing of HEMOBLAST™ Bellows, and completes bond financingJones Day represented Athyrium Capital Management in connection with the refinancing of Biom'Up's existing debt, financing of the production and marketing of its flagship product HEMOBLAST™ Bellows in the United States and the European Union, and the financing of its external growth.
  • Sunesis Pharmaceuticals successfully prosecutes U.S. patent for vosaroxinOn behalf of Sunesis Pharmaceuticals, Inc., Jones Day successfully prosecuted a U.S. patent application for vosaroxin which is used in the treatment of leukemia.
  • Genomatica establishes global patent portfolios related to production of more sustainable versions of major chemicals, made from alternative feedstocksJones Day represents Genomatica in the development of a worldwide patent portfolio related to methods of producing high-volume basic and intermediate chemicals from alternative feedstocks, such as sugars and cellulosic biomass, using engineered microorganisms.
  • BioMarin acquires LEAD TherapeuticsJones Day advised BioMarin Pharmaceutical, Inc. in connection with the acquisition of LEAD Therapeutics, Inc., a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers.
  • AstraZeneca prosecutes worldwide patent portfolio licensed from Nektar TherapeuticsJones Day assisted AstraZeneca LP in worldwide patent prosecution and portfolio management of a patent portfolio licensed from Nektar Therapeutics covering compounds for treating opioid-induced constipation.
    • View All

    July 2012 Commentaries

    Review of the Food and Drug Administration Safety and Innovation Act of 2012

    Speaking Engagements

    • March 27, 2019
      Intellectual Property and Plants

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.